• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[雷诺综合征的新疗法]

[New treatments for Raynaud's syndrome].

作者信息

Bellucci S, Kedra W, Ajzenberg N, Tobelem G, Caen J

机构信息

Départment d'Angiohématologie, Hôpital Lariboisière, Paris, France.

出版信息

Nouv Rev Fr Hematol (1978). 1988;30(1-2):103-7.

PMID:3290833
Abstract

Raynaud's phenomenon, either idiopathic or secondary is often severe. It is due to a vasospasm in response to cold, and an increase in sympathetic tone, hyperviscosity and sometimes hyperactivation of platelets and erythrocytes have been reported. New drugs have been developed such as ketanserin, which is a specific inhibitor of serotonin S2 receptors, and has led to a positive response in 38%-80% of patients. The prostaglandins PGE1 and PGI2 were given i.v. in refractory patients and led to a beneficial effect in 50%-70% of cases. These data seem to justify the development of prostaglandin analogues.

摘要

雷诺现象,无论是特发性还是继发性的,通常都很严重。它是由寒冷引起的血管痉挛所致,据报道,交感神经张力增加、血液高黏滞度,有时血小板和红细胞过度活化也与之相关。已研发出如酮色林等新药,它是5-羟色胺S2受体的特异性抑制剂,在38%-80%的患者中产生了阳性反应。对于难治性患者,静脉注射前列腺素PGE1和PGI2,50%-70%的病例有有益效果。这些数据似乎证明了前列腺素类似物研发的合理性。

相似文献

1
[New treatments for Raynaud's syndrome].[雷诺综合征的新疗法]
Nouv Rev Fr Hematol (1978). 1988;30(1-2):103-7.
2
Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
J Rheumatol. 1986 Apr;13(2):337-40.
3
New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
Angiology. 1993 Feb;44(2):123-8. doi: 10.1177/000331979304400206.
4
Pharmacological treatment of Raynaud's phenomenon with special reference to calcium-entry blockers.
Acta Pharmacol Toxicol (Copenh). 1986;58 Suppl 2:137-49. doi: 10.1111/j.1600-0773.1986.tb02529.x.
5
Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.前列腺素E1对比安慰剂治疗进行性系统性硬化症伴严重雷诺现象患者的疗效评估
Minerva Cardioangiol. 1999 May;47(5):137-43.
6
Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.酮色林对进行性系统性硬化症中雷诺现象的影响:一项双盲试验。
Drugs Exp Clin Res. 1985;11(9):659-63.
7
Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.酮色林治疗与原发性和继发性雷诺现象患者的血清素
Eur J Clin Pharmacol. 1988;35(4):419-21. doi: 10.1007/BF00561375.
8
Successful treatment of Raynaud's Syndrome with prostacyclin.前列环素成功治疗雷诺氏综合征。
Thromb Haemost. 1981 Jun 30;45(3):255-6.
9
[Calcium antagonists and Raynaud's phenomenon].[钙拮抗剂与雷诺现象]
Therapie. 1993 Nov-Dec;48 Spec No:707-11.
10
[Treatment of Raynaud's phenomenon].[雷诺现象的治疗]
Ann Dermatol Venereol. 1987;114(8):1035-8.